Selected conclusions of JECFA
Vaccination against hepatitis B would reduce the potency of aflatoxins to vaccinated populations and thus the risk of liver cancer
Detectable differences in population risks are unlikely to be exhibited in going from a hypothetical standard of 20 to 10 µg/kg in populations with a low prevalence of hepatitis B in which the mean intake of aflatoxins is low